Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

Inclusion Criteria: * Patients aged 20-70 years; * Diagnosed with AIH or primary biliary cirrhosis-autoimmune hepatitis overlap syndrome based on liver biopsy results and without indication of immunosuppressive therapy; * High levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)(1-3 X ULN); * High levels of IgG(1-1.5 X ULN); * Liver biopsy showed mild lymphocytic piecemeal necrosis (interface hepatitis); * Agreed to participate in the trial, and assigned informed consent. Exclusion Criteria: * The presence of hepatitis A, B, C, D, or E virus infection; * Patients with presence of liver cirrhosis or portal hypertension; * Patients with presence of fulminant liver failure; * Primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson disease confirmed by liver biopsy; * Pregnant and breeding women; * Severe disorders of other vital organs, such as severe heart failure, cancer; * Parenteral administration of blood or blood products within 6 months before screening; * Recent treatment with drugs having known liver toxicity; * Taken part in other clinic trials within 6 months before screening.